Series B AI companies in Paris

Charles River Labs has acquired Pathoquest, strengthening its end-to-end biologics testing portfolio with Next Generation Sequencing (NGS). Our GMP-compliant, animal-free NGS assays for viral safety and genetic characterization enable a faster and safer release of biotherapies to patients. Pathoquest, A Charles River Company, is a global CRO specializing in NGS-based Biosafety Quality Control through its iDTECT® assay platform, enabling the rapid and safe release of biotherapies to patients. The company offers validated GMP assays for viral safety testing and genetic characterization of raw materials, cell and gene therapies, monoclonal antibodies, and vaccines. Our testing services are available from facilities located in Paris, France, and Wayne, Pennsylvania.Your GMP Next-Gen Biosafety Partner. Compliant, Faster, Animal-Free.

• Series B
• 59 employees
• Founded 2010

The world’s population is estimated to reach more than nine billion by 2050. Global food production will have to increase by 70 per cent to feed everyone. Meanwhile one third of all food produced is wasted.At nextProtein we’re driven by a personal desire to address land and resource scarcity and feed a rising population sustainably. nextProtein can produce the equivalent amount of protein from 100sqm as 100ha of soya field.Founded by couple Syrine Chaalala and Mohamed Gastli, we produce insect-based protein for animal feedstocks with a negligible carbon footprint, at a lower cost and with the equivalent nutritional value of traditional protein production. We do this by taking otherwise unconsumed food on which to raise the insects, returning protein to the food cycle.nextProtein has years of experience in breeding Black Soldier Fly, which was selected specially for its beneficial, high-yield quality. Fly larvae are raised, harvested and then processed into valuable components of animal feed: an insect based protein for aquaculture, livestock and pets, an extracted fat and a natural fertilizer for use in agriculture.Our process is EU-approved for aquaculture and pet food and is suitable for feedstocks for the poultry and pork industries. Based in France with production operations in Tunisia, nextProtein is also backed by a range of high-profile international investors and business angels who have recognised our potential to revolutionise the industry.

• Series B
• 38 employees
• Founded 2015

BrainEver is a biopharmaceutical company developing a pipeline of novel therapies for patients with age-related neurodegenerative diseases, such as Charcot disease, Parkinson’s, and glaucoma, the second leading cause of blindness.Our mission is to develop recombinant human Homeoproteins (HPs) to halt disease progression by stopping neuronal loss and durably restoring the physiology and metabolism of the remaining neurons.BrainEver was co-founded by Bernard Gilly (iBionext) and Alain Prochiantz (Collège de France). Our innovative therapeutic approach stems from the pioneering work of Alain Prochiantz and his team on brain development and physiology.Our lead project, BREN02, focuses on developing recombinant human Engrailed-1 (hEN1) for the treatment of patients with Amyotrophic Lateral Sclerosis (ALS).Building on the highly promising results of our preclinical studies, we are preparing to launch clinical trials by 2025. Follow us!

• Series B
• 27 employees
• Founded 2015